Oculis Holding (OCS)
NASDAQ:OCS
Top Page
Oculis Holding
(NASDAQ:OCS)
Select Model
Select Model
Rating:53Neutral
Price Target:
$27.00
▼(-1.10% Downside)
Action:ReiteratedDate:03/07/26
The score is primarily held back by persistent losses and cash burn with limited revenue visibility, partially offset by a strong, low-debt balance sheet. Technicals are mixed (longer-term support but weaker near-term momentum), and valuation support is limited due to negative earnings and no dividend.
Positive Factors
Balance Sheet Strength
Extremely low leverage and a substantially larger equity base provide durable financial flexibility and lower solvency risk. This balance-sheet strength supports multi-year clinical programs, reduces bankruptcy risk, and preserves optionality for partnering or staged investment through 2–6 months and beyond.
Negative Factors
High Cash Burn
Sustained negative operating cash flow near -$60M annually reflects heavy R&D spending to support late-stage programs. Absent successful readouts or new financing, continued cash burn will erode resources and force financing decisions that could compromise strategic execution over the next 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Extremely low leverage and a substantially larger equity base provide durable financial flexibility and lower solvency risk. This balance-sheet strength supports multi-year clinical programs, reduces bankruptcy risk, and preserves optionality for partnering or staged investment through 2–6 months and beyond.
Read all positive factors
Oculis Holding (OCS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.56B
Dividend YieldN/A
Average Volume (3M)58.01K
Price to Earnings (P/E)―
Beta (1Y)0.36
Revenue GrowthN/A
EPS Growth-25.15%
CountryUS
Employees49
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.53
Shares Outstanding57,169,476
10 Day Avg. Volume127,612
30 Day Avg. Volume58,014
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue2.25K
Enterprise Value/Gross Profit-78.81
Enterprise Value/Ebitda-11.91
Forecast
1Y Price Target
$47.25Price Target Upside73.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.75
Revenue Forecast (FY)$4.71M
Oculis Holding Business Overview & Revenue Model
Company Description
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in ...
How the Company Makes Money
Oculis generates revenue through the development and commercialization of its ophthalmic products. The primary revenue streams include sales of its proprietary drug formulations, licensing agreements with pharmaceutical companies, and collaboratio...
Oculis Holding Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 686.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -51.40M | 0.00 | 0.00 | 0.00 |
| EBITDA | -79.15M | -72.80M | -87.09M | -31.90M | -13.17M |
| Net Income | -94.51M | -85.78M | -88.80M | -38.70M | -18.55M |
Balance Sheet | |||||
| Total Assets | 236.23M | 120.35M | 114.35M | 37.06M | 58.04M |
| Cash, Cash Equivalents and Short-Term Investments | 213.25M | 98.66M | 91.65M | 19.79M | 46.28M |
| Total Debt | 2.32M | 1.18M | 605.00K | 123.08M | 114.27M |
| Total Liabilities | 39.94M | 46.97M | 20.63M | 135.05M | 119.00M |
| Stockholders Equity | 196.29M | 73.38M | 93.73M | -97.99M | -60.95M |
Cash Flow | |||||
| Free Cash Flow | -62.51M | -47.73M | -53.89M | -28.62M | -13.85M |
| Operating Cash Flow | -62.22M | -47.50M | -53.84M | -25.07M | -13.82M |
| Investing Cash Flow | -59.38M | -17.56M | -54.21M | -3.55M | -28.00K |
| Financing Cash Flow | 178.60M | 54.03M | 129.67M | 1.71M | 55.19M |
Oculis Holding Technical Analysis
Positive
27.30
Price Trends
27.37
Negative
24.39
Positive
21.48
Positive
Market Momentum
0.03
Negative
56.09
Neutral
81.90
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OCS, the sentiment is Positive. The current price of 27.3 is above the 20-day moving average (MA) of 25.90, below the 50-day MA of 27.37, and above the 200-day MA of 21.48, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 56.09 is Neutral, neither overbought nor oversold. The STOCH value of 81.90 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OCS.
Oculis Holding Risk Analysis
Oculis Holding disclosed 95 risk factors in its most recent earnings report. Oculis Holding reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oculis Holding Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $8.80B | -21.87 | -58.74% | ― | 364.98% | -25.33% | |
60 Neutral | $4.03B | -45.32 | -29.44% | ― | ― | -123.65% | |
53 Neutral | $1.56B | -8.77 | -62.46% | ― | ― | -25.15% | |
52 Neutral | $1.18B | -5.61 | -88.31% | ― | -7.38% | -49.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $570.87M | -10.19 | -36.48% | ― | ― | ― | |
48 Neutral | $799.34M | -6.70 | -100.29% | ― | 5459.66% | -59.70% |
* Healthcare Sector Average
OCS
Oculis Holding
27.30
9.37
52.26%
EYPT
EyePoint Pharmaceuticals
14.19
8.52
150.26%
SYRE
Spyre Therapeutics
51.29
38.58
303.54%
PRAX
Praxis Precision Medicines
316.14
286.47
965.52%
SPRY
ARS Pharmaceuticals
8.05
-6.94
-46.30%
UPB
Upstream Bio, Inc.
10.49
2.72
35.01%
Oculis Holding Corporate Events
Oculis Files 2025 Financials and Renews $100 Million ATM Program
Mar 4, 2026
On March 4, 2026, Oculis Holding AG filed its 2025 IFRS consolidated and statutory financial statements, which received an unqualified audit opinion confirming a true and fair view under IFRS and Swiss law. The audit highlighted research and devel...
Oculis Posts 2025 Results, Extends Cash Runway and Advances Late-Stage Ophthalmology Pipeline
Mar 3, 2026
On March 3, 2026, Oculis reported its fourth-quarter and full-year 2025 results, highlighting a transformative year marked by clinical advances and a strengthened balance sheet. Cash, cash equivalents and short-term investments rose to $268.7 mill...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.